Organon & Co. (OGN) Stock: A Closer Look at the Analyst Ratings

Organon & Co. (NYSE: OGN) has a price-to-earnings ratio of 4.54x that is above its average ratio. Additionally, the 36-month beta value for OGN is 0.79. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The public float for OGN is 255.25M and currently, short sellers hold a 3.97% ratio of that float. The average trading volume of OGN on April 03, 2024 was 2.89M shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

OGN) stock’s latest price update

Organon & Co. (NYSE: OGN) has seen a decline in its stock price by -2.00 in relation to its previous close of 18.50. However, the company has experienced a 1.74% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-03-14 that Now may be an ideal time to buy these lower-risk, high-income stocks especially as markets start to digest hot inflationary data.

OGN’s Market Performance

Organon & Co. (OGN) has experienced a 1.74% rise in stock performance for the past week, with a 3.25% rise in the past month, and a 25.73% rise in the past quarter. The volatility ratio for the week is 2.14%, and the volatility levels for the past 30 days are at 2.49% for OGN. The simple moving average for the last 20 days is -0.18% for OGN stock, with a simple moving average of 4.08% for the last 200 days.

Analysts’ Opinion of OGN

Many brokerage firms have already submitted their reports for OGN stocks, with Goldman repeating the rating for OGN by listing it as a “Neutral.” The predicted price for OGN in the upcoming period, according to Goldman is $16 based on the research report published on November 03, 2023 of the previous year 2023.

Barclays, on the other hand, stated in their research note that they expect to see OGN reach a price target of $28. The rating they have provided for OGN stocks is “Overweight” according to the report published on September 21st, 2023.

Raymond James gave a rating of “Outperform” to OGN, setting the target price at $33 in the report published on March 16th of the previous year.

OGN Trading at 3.45% from the 50-Day Moving Average

After a stumble in the market that brought OGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.87% of loss for the given period.

Volatility was left at 2.49%, however, over the last 30 days, the volatility rate increased by 2.14%, as shares surge +4.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.97% upper at present.

During the last 5 trading sessions, OGN rose by +1.74%, which changed the moving average for the period of 200-days by -10.65% in comparison to the 20-day moving average, which settled at $18.20. In addition, Organon & Co. saw 25.73% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at OGN starting from Weaver Kirke, who purchase 2,720 shares at the price of $18.36 back on Feb 22 ’24. After this action, Weaver Kirke now owns 15,181 shares of Organon & Co., valued at $49,939 using the latest closing price.

Stock Fundamentals for OGN

Current profitability levels for the company are sitting at:

  • 0.1 for the present operating margin
  • 0.6 for the gross margin

The net margin for Organon & Co. stands at 0.16. The total capital return value is set at 0.07.

Based on Organon & Co. (OGN), the company’s capital structure generated 1.01 points at debt to capital in total, while cash flow to debt ratio is standing at 0.09. The debt to equity ratio resting at -125.14. The interest coverage ratio of the stock is 1.22.

Currently, EBITDA for the company is 1.55 billion with net debt to EBITDA at 5.87. When we switch over and look at the enterprise to sales, we see a ratio of 2.03. The receivables turnover for the company is 3.59for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.54.

Conclusion

In conclusion, Organon & Co. (OGN) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts